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Abstract 
Controlling pharmaceutical polymorphism in crystallization processes represents a major challenge 
in pharmaceutical science and engineering. For instance, CO2-antisolvent crystallization typically 
favors the formation of metastable forms of carbamazepine (CBZ), a highly polymorphic drug, with 
impurities of other forms. This work demonstrates for the first time that a supercritical CO2-
antisolvent crystallization process in combination with certain molecular additives allows control of 
the polymorphic outcome of carbamazepine. We show herein that in the presence of sodium stearate 
and Eudragit L-100, needle-shaped crystals of CBZ form II are obtained, while blocky-shaped 
crystals of CBZ form III are obtained in the presence of Kollidon VA64, sodium dodecyl sulfate, 
ethyl cellulose and maltitol.  This selectivity for pure forms in this supercritical set up contrasts to 
the results when the same set of additives where used in a solvent evaporation method that yielded 
mixtures of form I, II and III.  The type of additive used in the CO2-antisolvent crystallization 
process impacted both the product crystals polymorphic form and size. A detailed molecular-level 
analysis along with DFT calculations allowed us to give a mechanistic insight into the role of 
sodium stearate and Eudragit L-100 in facilitating nucleation of the metastable form II. 
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analysis along with DFT calculations allowed us to give a mechanistic insight into the role of 
sodium stearate and Eudragit L-100 in facilitating nucleation of the metastable form II. 
 
Keywords 
Supercritical antisolvent, carbamazepine, additives, nucleation, crystallization, polymorphism. 
 
Introduction 
The ability of an API (Active Pharmaceutical Ingredient) to crystallize or interconvert into distinct 
polymorphic forms during processing or shelf life has emerged as a major concern for the 
pharmaceutical industry [1, 2]. As polymorphism is one of the key controlling factors directly 
impacting the processability of a drug substance and the quality, safety and efficacy of a drug 
product, there is an ever increasing need to both understand and control pharmaceutical 
crystallization processes. 
Polymorphism is influenced by several factors including processing conditions such as temperature, 
pressure, type of solvent and antisolvent, supersaturation and the presence of molecular additives or 
impurities [3, 4]. The use of additives in pharmaceutical crystallization is of high importance 
particularly to the industry due to their ability to favor the nucleation and crystal growth of a 
particular crystalline form with the desired physicochemical properties, while inhibiting the 
formation of another crystalline form [5, 6]. Molecules of an additive may potentially be 
incorporated into the crystal lattice of an API and influence its crystallization processes [7]. Some 
publications have highlighted the ability of different types of impurities or additives to not only 
influence the polymorphic outcome in a crystallization process but also the crystals morphology and 
size [8-11]. However, the mechanisms involved in the additive-mediated crystal growth and 
polymorphic transformations are still unknown in many cases.  
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Conventional crystallization techniques such as cooling crystallization or solvent evaporation have 
the disadvantage of providing slow nucleation and crystal growth kinetics, taking a long time to 
produce crystals. However, these methods may potentially favor the formation of more stable 
polymorphic forms instead of metastable ones and typically generate larger crystals [12]. Antisolvent 
techniques, which consist of adding a non-solvent to a saturated solution to induce the precipitation 
of the solute, provide much faster nucleation and crystallization kinetics, typically favoring the 
formation of metastable polymorphic forms and smaller crystals [13-15]. Water is typically used as 
an antisolvent for the crystallization of poorly-soluble APIs. However, when using water as a liquid 
antisolvent the final suspension needs to be filtered and dried or directly spray-dried to obtain the 
final powder, and depending on API used there is the risk of forming a hydrate during processing 
[16-18]. Using supercritical CO2 as the antisolvent there is no risk of forming hydrates [19] and the 
remaining organic solvent is removed from the final product during flushing with CO2 after the 
crystallization process, providing a solvent-free dried product [20, 21].  
CBZ, a first generation anticonvulsant used in the treatment of epilepsy and trigeminal neuralgia, is 
an interesting model system for the study of crystallization processes due to its ability to generate 
distinct solid state forms such as polymorphs, hydrates, salts and cocrystals. CBZ exists in at least 
four anhydrous polymorphs (I, II, III and IV), with form III being the most stable polymorph under 
ambient conditions. The literature provides some examples on the crystallization of CBZ 
polymorphs by traditional crystallization methods such as cooling crystallization and solvent 
evaporation, including the use of additives or functionalized templates aiming to control the final 
polymorphic form obtained [22-26]. However, these methods provide slow crystallization kinetics 
and require the use of additional filtration and drying steps to remove the residual organic solvent 
from the final particles. CBZ crystals have been also produced using supercritical CO2 antisolvent 
method, however the samples obtained in that study represented mixtures of several metastable 
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polymorphic forms (I, II) with some impurities from form III [27]. To the best of our knowledge 
there has been no systematic study published in the literature which: (i) addresses the use of CO2 
antisolvent methods to successfully obtain distinct PXRD-pure polymorphic forms of CBZ, and (ii) 
addresses the use of molecular additives in CO2 antisolvent methods to provide control over the 
CBZ polymorphic form obtained. 
This paper aims to answer the following questions: is it possible to control the polymorphic outcome 
of CBZ by using molecular additives in a supercritical CO2 antisolvent crystallization process? 
Which mechanisms are involved between solvent, API and additive molecules in a CO2 antisolvent 
method for favoring the formation of a particular polymorph whilst inhibiting the formation of 
another? 
In this work a gas antisolvent (GAS) process is used to crystallize distinct carbamazepine (CBZ) 
polymorphs from methanol solutions containing molecular additives. The results are compared with 
those obtained using a traditional crystallization process (solvent evaporation). A detailed analysis of 
the relevant CBZ crystal structures along with molecular modelling using Density Functional Theory 
(DFT) have been applied in order to gain insight into molecular mechanisms by which the additives 
govern the polymorphic outcome of CBZ. 
 
Experimental Section 
Materials 
Carbamazepine (verified to be Form III by reflection powder X-ray diffraction), sodium stearate, 
Pluronic F-127, sodium dodecyl sulfate, ethyl cellulose, Polysorbate 80, PVP360, PEG 400 and 
HPMC were purchased from Sigma Aldrich and used without further purification (purity was 
>99.9%). Kollidon VA 64 was obtained from BASF, PEG 3400 was obtained from Polysciences and 
HPC (Klucel) was obtained from Ashland. Eudragit L-100, Eudragit L-100-55 and Eudragit EPO 
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were a generous gift from Evonik Industries. Carbon dioxide (99.98%) was supplied by BOC 
(Ireland). Table 1 summarizes the different types of additives used in this work. 
 
Table 1 – Type of additives used in the preparation of carbamazepine solutions in methanol for gas 
antisolvent (GAS) and/or solvent evaporation (SV) processing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SDS: Sodium Dodecyl Sulfate; PVP: Polyvinylpyrrolidone; HPMC: Hydroxypropylmethylcellulose; 
HPC: Hydroxypropylcellulose; PEG: Polyethylene Glycol.  
 
Solution preparation 
Carbamazepine (CBZ) with/without additives was dissolved in methanol (70.0 mg in 1 mL of 
methanol) using moderate shaking with a vortex and ultrasonic treatment (~5 min). When using 
additives for the preparation of the CBZ solutions, 5% w/w (~4.0 mg) of each additive were 
dissolved in the CBZ solutions. The solutions were then filtered through a 0.2 µm pore size nylon 
filter (Whatman Inc., Florham Park, NJ) to remove any undissolved material. Table 2 shows the 
experimental conditions used in the preparation of the CBZ solutions prior being processed by gas 
antisolvent (GAS) or solvent evaporation (SV). The GAS and SV experiments were performed three 
times, except for the experiments where pure polymorphs II or III of carbamazepine have been 
Anionic 
surfactants 
Non-ionic surfactants 
Anionic 
polymers 
Non-ionic 
polymers 
Sodium stearate Pluronic F-127 Eudragit L-100 Ethyl cellulose 
SDS Polysorbate 80 
Eudragit L-100-
55 
HPMC 
- Maltitol Eudragit EPO HPC 
- Kollidon VA64 - PVP360 
- - - PEG 400 
- - - PEG 3400 
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obtained (GAS 2, 4, 7, 8, 9 and 10 – see Table 3) which were performed at least 6 times. 
 
Table 2 - Experimental conditions used in the preparation of carbamazepine solutions in methanol 
for gas antisolvent (GAS) and solvent evaporation (SV) methods. For GAS experiments pressure 
was 90 bar, temperature was 40ºC, magnetic stirring rate was 300 rpm and CO2 addition rate was 
1.52 g/s. Ratio of additive to total solids (CBZ + additive) used in GAS and SV experiments was 5 
% (w/w). 
 
 
CBZ: carbamazepine; SDS: Sodium Dodecyl Sulfate; PVP: Polyvinylpyrrolidone; HPMC: 
Hydroxypropylmethylcellulose; HPC: Hydroxypropylcellulose; PEG: Polyethylene Glycol. 
Sample 
Reference 
Additive 
Processing 
technique 
Mass CBZ (mg) 
Mass additive 
(mg) 
GAS 1 - GAS 70.0 - 
GAS 2 Sodium stearate GAS 70.0 3.7 
GAS 3 Pluronic F-127 GAS 70.0 3.7 
GAS 4 Eudragit L-100 GAS 70.0 3.7 
GAS 5 Eudragit L-100-55 GAS 70.0 3.7 
GAS 6 Eudragit EPO GAS 70.0 3.7 
GAS 7 Kollidon VA 64 GAS 70.0 3.7 
GAS 8 SDS GAS 70.0 3.7 
GAS 9 Ethyl Cellulose GAS 70.0 3.7 
GAS 10 Maltitol GAS 70.0 3.7 
GAS 11 PVP360 GAS 70.0 3.7 
GAS 12 HPMC GAS 70.0 3.7 
GAS 13 HPC (Klucel) GAS 70.0 3.7 
GAS 14 Polysorbate 80 GAS 70.0 3.7 
GAS 15 PEG 400 GAS 70.0 3.7 
GAS 16 PEG 3400 GAS 70.0 3.7 
SV 1 - SV 70.0 - 
SV 2 Sodium stearate SV 70.0 3.7 
SV 3 Pluronic F-127 SV 70.0 3.7 
SV 4 Eudragit L-100 SV 70.0 3.7 
SV 5 Kollidon VA 64 SV 70.0 3.7 
SV 6 SDS SV 70.0 3.7 
SV 7 Ethyl Cellulose SV 70.0 3.7 
SV 8 Maltitol SV 70.0 3.7 
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Gas antisolvent crystallization (GAS)  
Figure 1 shows a schematic diagram of a custom-built batch gas antisolvent (GAS) apparatus. It 
consists essentially of a 100 cm3 stainless steel storage vessel and a 10 cm3 stainless steel high-
pressure vessel (where the crystallization experiments take place) with monitored temperature and 
pressure using a T-type thermocouple and a pressure transducer (Omega model PX603), 
respectively. These vessels are placed inside a temperature-controlled air chamber. A borosilicate 
window was placed over the top of the high-pressure vessel for visualization purposes during the 
experiments.  
 
 
Figure 1 - Schematic diagram of the batch supercritical antisolvent apparatus. 1, gas cylinder; 2, gas 
compressor; 3, back-pressure controller; 4, gas storage vessel; 5, high-pressure vessel; 6, magnetic 
stirrer. 
 
A Teledyne ISCO 260D pump was used to load the CO2 into the storage vessel before being 
introduced into the high-pressure vessel. A solution containing 70 mg of CBZ dissolved in 1mL of 
methanol with/without an additive was placed inside the high-pressure vessel and compressed with 
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CO2 up to the desired pressure and temperature until crystallization takes place. During the addition 
of CO2, the solutions were subjected to magnetic stirring at 300 rpm to improve the mixing between 
the CO2 and the solution. When supersaturation is reached and crystallization takes place, magnetic 
stirring is turned off and the valve which links to the vent is opened to continuously flush 
supercritical CO2 through the high-pressure vessel out to the vent (in order to remove the methanol 
from the samples). CO2 was flushed through the high-pressure vessel during 1 hour at a flow-rate of 
approximately 10ml/min. After flushing was completed, the high-pressure vessel was slowly 
depressurized and the resulting material was collected. 
The samples obtained from the experiments were stored in a closed desiccator prior to its 
characterization. 
 
Solvent evaporation (SV) crystallization 
According to Table 2, 1 ml of each solution was prepared, inserted in an eppendorf tube and placed 
inside a fume hood with the cap open overnight (approx. for 12 hours) to allow the solution to 
evaporate. On the next day, the powder from each eppendorf tube was collected and stored in a 
closed desiccator prior to its characterization. 
 
Solid-state characterization 
PXRD in reflection mode was performed using an Empyrean diffractometer (PANalytical, Phillips) 
with Cu Kα radiation (λ = 1.5406 Å) at room temperature. Samples were lightly ground and pressed 
on a zero-background plate prior to analysis. Data were recorded at a tube voltage of 40 kV and a 
tube current of 40 mA, with a step size of 0.02° (2θ) and a scan speed of 0.102° (2θ·s–1) in the 
angular range of 5° to 40° (2θ) with 4 rpm. 
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Scanning Electron Microscopy (SEM) was performed using a JEOL Carryscope scanning electron 
microscope JCM-5700. Samples were mounted onto aluminum stubs with carbon tabs and coated by 
an ultrathin gold layer prior to analysis. 
 
Raman spectra of solid samples were collected using a Kaiser Raman Rxn2 analyzer with an 
Invictus 785 nm excitation laser and a CCD camera-based detector. A noncontact half-inch probe 
was used and each spectrum was collected for a minimum of 30 s exposure time and six 
accumulations in the region of 3400 cm–1 to 100 cm–1 using Mettler Toledo iC Raman software 
version 4.1. 
 
Crystal size distributions were obtained by analyzing images obtained from a Zeiss optical 
microscope using the ImageJ software. 
 
Molecular modelling 
Density functional theory (DFT) calculations were applied using a Gaussian 09 package [28] to 
investigate strength of interaction between molecules forming (1:1) associates (dimers) of sodium 
stearate-methanol and sodium dodecyl sulfate-methanol at the polar ‘heads’ of the surfactants, and 
sodium stearate-CBZ and sodium dodecyl sulfate-CBZ at both the polar ‘heads’ and the non-polar 
‘tails’ of the surfactants. In addition (1:1) binding interactions are quantified for CBZ-CBZ, CBZ-
acetic acid, CBZ-methanol, and CBZ-CO2 associates. The equilibrium geometries (gas-phase) are 
calculated with a B97-D3 Grimme’s functional [29], and a Gaussian-type 6-31G(d,p) basis set [30]. 
The (1:1) binding energy in a dimer is calculated as follows: 
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 ∆Ebind = EAB – (EA + EB)    [1] 
Where EAB is the energy of a dimer AB and EA and EB are energies of the isolated molecules A and 
B, both being in fully relaxed gas-phase geometries. The DFT energies are calculated using a double 
hybrid B2PLYP-D3 functional [31], which combines exact Hartree-Fock exchange with an MP2-
like correlation and long-range dispersion corrections; here we use a basis set of quadruple-ζ valence 
quality (def2-QZVPP) [32].  This methodology has been successfuly applied for small and medium-
sized API molecules in recent nucleation studies on salicylic acid [33], parabens [34], and 
risperidone [35].  
The molecular structures were visualized using Materials Studio 7.0 from Accelrys Inc. 
 
Results and Discussion 
Crystallization of carbamazepine (CBZ) by gas antisolvent (GAS) and solvent evaporation (SV) 
Table 2 shows the experimental conditions used for the preparation and processing of 
carbamazepine solutions by GAS and SV methods, while Table 3 summarizes the related CBZ 
crystalline forms obtained. The results show that in the absence of excipients both GAS and SV 
methods generated the stable form of CBZ (form III) however with traces of its metastable forms (I, 
II) (Figure 2).  
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Table 3 – List of carbamazepine (CBZ) solid forms obtained using gas antisolvent (GAS) and 
solvent evaporation (SV) methods. For GAS experiments pressure was 90 bar, temperature was 
40ºC, magnetic stirring rate was 300 rpm and CO2 addition rate was 1.52 g/s. Ratio of additive to 
total solids (CBZ + additive) used in GAS and SV experiments was 5 % (w/w). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CBZ: carbamazepine; SDS: Sodium Dodecyl Sulfate; PVP: Polyvinylpyrrolidone; HPMC: 
Hydroxypropylmethylcellulose; HPC: Hydroxypropylcellulose; PEG: Polyethylene glycol.  
 
 
Sample 
Reference 
Additive 
Processing 
technique 
Solid form 
obtained 
GAS 1 - GAS II + III 
GAS 2 Sodium stearate GAS II 
GAS 3 Pluronic F-127 GAS II + III 
GAS 4 Eudragit L-100 GAS II 
GAS 5 Eudragit L-100-55 GAS II + III 
GAS 6 Eudragit EPO GAS II + III 
GAS 7 Kollidon VA 64 GAS III 
GAS 8 SDS GAS III 
GAS 9 Ethyl Cellulose GAS III 
GAS 10 Maltitol GAS III 
GAS 11 PVP360 GAS II + III 
GAS 12 HPMC GAS II + III 
GAS 13 HPC (Klucel) GAS II + III 
GAS 14 Polysorbate 80 GAS II + III 
GAS 15 PEG 400 GAS II + III 
GAS 16 PEG 3400 GAS II + III 
SV 1 - SV I + III 
SV 2 Sodium stearate SV I + II + III 
SV 3 Pluronic F-127 SV I + II + III 
SV 4 Eudragit L-100 SV I + II + III 
SV 5 Kollidon VA 64 SV I + III 
SV 6 SDS SV I + III 
SV 7 Ethyl Cellulose SV I + III 
SV 8 Maltitol SV I + III 
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Figure 2 – Powder X-ray diffraction patterns of distinct CBZ polymorphic forms (I, II and III) from 
CSD (Cambridge Structural Database), raw CBZ and CBZ samples produced by the GAS (GAS 1) 
and SV (SV 1) methods without using additives. 
 
Due to the difficulties in obtaining pure polymorphic forms of CBZ from methanol solutions in 
preliminary experiments (GAS 1 and SV 1) using either GAS or SV methods, distinct types of 
excipients/additives were selected (Table 1) and dissolved together with CBZ in methanol for the 
GAS experiments (GAS 2 to 16 listed in Tables 2 and 3) in order to assess their impact on the final 
polymorphic form of CBZ. Table 3 lists the CBZ polymorphic forms which have been obtained by 
GAS using the different additives. Interestingly, the GAS experiments, in which sodium stearate 
(GAS 2) and Eudragit L-100 (GAS 4) were used as additives, yielded PXRD pure CBZ form II. In 
contrast, PXRD pure CBZ form III was obtained when using Kollidon VA64 (GAS 7), sodium 
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dodecyl sulfate (GAS 8), ethyl cellulose (GAS 9), and maltitol (GAS 10). These experiments were 
repeated at least 6 times and provided a high reproducibility on the final CBZ polymorphic form 
obtained (100%). On the contrary, other additives i.e. Pluronic F-127, Eudragit L-100-55, Eudragit 
EPO, PVP360, HPMC, HPC, Polysorbate 80, PEG 400 and PEG 3400 led to mixtures of CBZ forms 
II and III.  
The additives which provided pure polymorphic forms of CBZ by GAS were further used in the SV 
experiments for comparison purposes. Figure 3 shows the PXRD patterns for all GAS experiments 
respectively (experimental conditions used in these experiments are listed in Tables 2 and 3). 
Although the different polymorphs feature a number of distinct peak positions and intensities, the 
most characteristic for the identification of form II is the peak appearing at ca. 5º (2 Theta) in a 
PXRD diffractogram.   
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Figure 3 – Powder X-ray diffraction patterns of distinct CBZ polymorphic forms (I, II and III) from 
CSD (Cambridge Structural Database) and CBZ samples produced by the GAS method (GAS 1 to 
16). 
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Figure SI1 in the Supporting Information shows that, using the same set of additives as used in GAS, 
no pure polymorphs were obtained in the SV experiments. This is in contrast to the GAS 
experiments, where either pure form II or form III was observed in certain cases (see Table 3).  
Noteworthy, the GAS method provides much faster crystallization times than the SV process. Using 
a CO2 addition rate of 1.52 g/s the pressure inside the high-pressure vessel goes from 1 bar to 90 bar 
in approximately one second, inducing the precipitation of CBZ crystals during that time frame. As 
supercritical CO2 has a good miscibility with many organic solvents including methanol, it easily 
dissolves in the methanol solution during the crystallization step. Subsequently, the CO2 antisolvent 
removes the methanol from the high-pressure vessel during a flushing step. As a result, the CBZ 
particles have progressively less and less methanol molecules in their surroundings. If the 
polymorphic transformation to form III is solvent-mediated [36], this could be another argument 
(besides the kinetic factor) explaining why the GAS method does not yield the form III crystals.  
Taking into account that the processing parameters in the GAS method are the same in all the 
experiments, it appears that the observed pure CBZ form II  being obtained in the presence of 
sodium stearate and Eudragit L-100 results from the efficient promotion and stabilization of the 
metastable form II by these two particular additives. Notably, in presence of these two particular 
excipients, the form II appears in the crystallization mixture as well when using the SV method. This 
suggests that, regardless of the crystallization method, the CBZ form II crystals can form only if 
sodium stearate or Eudragit L-100 is present in the crystallization solution.  
 
 
Particle size and shape of CBZ crystals produced by GAS 
Figure 4 shows SEM images of selected CBZ samples produced by the GAS method (see Table 2).  
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Figure 4 – Scanning Electron Microscopy images of CBZ crystals produced from different GAS 
runs: (a) GAS 1; (b) GAS 15; (c) GAS 2; (d) GAS 4; (e) GAS 7; (f) GAS 8; (g) GAS 9; (h) GAS 10. 
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The SEM analysis corroborates the PXRD results. The CBZ samples which contain mixtures of 
CBZ forms II and III (e.g. GAS 1 (no additives) and GAS 15 (PEG 400)) are composed of 
intermixed particles: needles (form II) and block-shaped (form III) particles (Figs. 4a and 4b, 
respectively). In contrast, the CBZ samples crystallized with sodium stearate (Fig. 4c, GAS 2) and 
Eudragit L-100 (Fig. 4d, GAS 4) as additives, show needle/rod shaped particles only, being 
characteristic of the CBZ form II. On the other hand, CBZ crystallized in presence of Kollidon VA 
64 (Fig. 4e, GAS 7), SDS (Fig. 4f, GAS 8), Ethyl Cellulose (Fig. 4g, GAS 9), and Maltitol (Fig. 4h, 
GAS 10), features blocky-shaped crystals, typical of the CBZ form III [36]. 
The most pronounced differences in the distribution of particle sizes have been observed for the 
blocky crystals of form III generated with the GAS method. In order to assess an impact of the 
additive type on the crystal size distributions we have employed image analysis (Fig. SI2 in the 
Suppporting Information). It appears that CBZ particles produced in presence of SDS (GAS 8) had 
smaller sizes with relatively narrow size distribution. On the other hand, the largest CBZ crystals 
with broadest size distribution were produced with Maltitol (GAS 10). 
 
Molecular-level analysis 
A carbamazepine molecule has amphiphilic character as its one part features polar groups (carbonyl, 
C=O, and amide, NH2), which are capable of forming strong H-bonds, while the other part is 
predominantly hydrophobic, being made of three conjugated hydrocarbon rings. Two CBZ 
molecules tend to form a symmetric dimer through double C=O…H-N H-bonding. Interestingly, 
such a dimer is a building block (a synthon) present in all the three polymorphs (Fig. 5). It is 
commonly accepted that hydrogen bonds formed between polar groups are strong and directional, in 
contrast to much weaker and less directional interactions of non-polar hydrocarbon hydrogens. Thus 
the strongest interactions in all the three crystal lattices are actually those between the two molecules 
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forming a dimer. A common feature of the polymorph I and polymorph II is the formation of 
columns made of stacked CBZ dimers. The columnar stacking results in proximity of polar groups 
of adjacent dimers. On the other hand, in the form III crystal the CBZ dimers are not stacked into 
columns; this results in a separation of the polar groups by non-polar domains (rings) of the CBZ 
molecules (Fig. 5).  
A feature which distinguishes form II from the other two polymorphs is the presence of empty 
channels with a diameter of ca. 7 Å, being parallel to the crystallographic c-axis. The walls of the 
channels are made of non-polar rings of CBZ molecules; this is an interesting feature which will 
further be discussed in relation to the question why the polymorph II nucleates in the presence of 
particular polymeric additives.  
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Figure 5 - A carbamazepine dimer (top) and molecular packing in the carbamazepine crystals (CBZ) 
of form I, form II, and form III (left panel). The CBZ dimers are arranged either in columns (form I 
and form II) or create a non-columnar arrangement (form III) – right panel. Carbon – grey, hydrogen 
– white, nitrogen – blue, oxygen – red. 
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Figure 6 - Vacuum morphology (computational prediction, COMPASS-II force-field) of 
carbamazepine (CBZ) crystal form I, form II and form III. An arrangement of the CBZ molecules in 
each of the simulated crystalline particles is also highlighted. 
 
Our computationally-derived models show that the columnar stacking arrangement of the dimers as 
observed in form I and form II crystals leads to elongated rod-like particles, while the non-columnar 
orientation of CBZ molecules results in a blocky-shaped particle (Fig. 6). The predicted rod-like 
particles of form I and form II crystals and the blocky particles of form III crystals closely match the 
experimentally-observed morphologies of form I and form II (elongated rods/needles) and form III 
(blocks) [36]. Thus, it appears that at the employed experimental conditions the shape analysis of the 
crystalline particles can be used to distinguish form III from the other two polymorphs.  
 
When looking at the polymeric additives that lead to nucleation of either form II or form III (Fig. 7), 
it is difficult to find any common structural factor which could explain why one set of polymers lead 
to a particular polymorph. This suggests that, among the additives studied, there is probably more 
than one mechanism to govern the nucleation of CBZ into a particular polymorph. The structural 
complexity and size of polymeric additives makes molecular modelling very challenging. For this 
reason, in our modelling work we have focused on two surfactants which lead to distinct polymorphs 
of CBZ: sodium stearate (form II promoter) and sodium dodecyl sulfate (form III promoter). 
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Figure 7 - Structural details of the polymeric additives which promote the formation of either pure 
carbamazepine form II or form III when using a gas (supercritical CO2) antisolvent crystallization 
process.  
  
Sodium stearate consists of a hydrocarbon tail (17-carbon) and a sodium carboxylate end 
(COO‒Na+), while sodium dodecyl sulfate consists of a 12-carbon tail attached to a sodium sulfate 
end (SO4
‒Na+). Our DFT calculations indicate that both CBZ and methanol interact stronger with the 
sodium sulfate part of the SDS molecule as compared to weaker binding to the COO‒Na+ group of 
sodium stearate (Fig. 8). The possible reason can be that in the case of SDS, the amine hydrogen of 
the CBZ molecule (H-bond donor) interacts with two oxygens of the SO4 group, whereas in sodium 
stearate there is only one carboxylic oxygen, which is involved in the bonding.  
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The binding interactions of the polar ‘heads’ of both the surfactants are significantly stronger to CBZ 
(-117.1 kJ/mol for SDS-CBZ and -92.0 kJ/mol for sodium stearate-CBZ) than to methanol (-71.0 
kJ/mol for SDS-methanol and -66.5 kJ/mol for sodium stearate-methanol). This suggests that, in 
methanol solution, CBZ molecules would preferentially bind to the polar/ionic parts of the surfactant 
molecules. Overall the stability order of the dimers as judged by the interaction strength is: 
surfactant-CBZ > CBZ-CBZ > CBZ-methanol. This suggests that the CBZ dimers might 
preferentially form in the presence of methanol (but in the absence of surfactant). However, if 
surfactant is present, the formation of the surfactant-CBZ complex would be energetically more 
preferential over both the CBZ-CBZ and CBZ-methanol dimers.  
In the GAS process, carbon dioxide is being used as antisolvent. It is well known that, due to its non-
polar nature, CO2 molecules are incapable of forming strong intermolecular bonds. This is clearly 
reflected in the lowest binding energy (-11.4 kJ/mol) calculated for the CBZ-CO2 associate (Fig. 8). 
It seems that the low interaction strength makes the CO2 molecules fairly inert and non-competitive 
towards interactions with polar sites of CBZ, in contrast to much stronger interacting molecules of 
methanol and surfactants. If looking at polar ‘heads’ of the two surfactants it appears that the 
sulfonyl group in SDS contains four oxygen atoms capable of interacting with the amine protons of 
CBZ, compared to two oxygens present in the sodium stearate carboxylic group. Accordingly, SDS 
can potentially bind to at least three CBZ molecules, while sodium stearate can make a strong 
bonding with maximum two CBZ molecules.  
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Figure 8 - DFT binding energies calculated for (1:1) molecular associates of sodium stearate‒ 
carbamazepine (CBZ), sodium stearate‒methanol, sodium dodecyl sulfate‒CBZ, sodium dodecyl 
sulfate‒methanol, CBZ‒CBZ, CBZ‒acetic acid, CBZ‒methanol, and CBZ-CO2. Calculations 
performed at B97-D3/6-31G(d,p) level (geometry) and B2PLYP-D3/def2-QZVPP level (energy). 
Carbon – grey, hydrogen – white, nitrogen – blue, oxygen – red, sulfur – yellow, sodium – purple. 
 
As expected, the aliphatic ‘tails’ of both the surfactants exhibit significantly weaker interactions with 
the non-polar parts of the CBZ molecule, ranging from -0.6 kJ/mol to -7.5 kJ/mol (Figure 9). Our 
calculations also show that the perpendicular orientation of the CBZ–surfactant pair yields relatively 
stronger binding energy than the parallel stacking of the molecules. In the latter case the binding 
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strength of the CBZ molecule to SDS and to sodium stearate is comparable (7.0 kJ/mol vs 7.5 
kJ/mol).  
 
Figure 9 - DFT binding energies calculated for (1:1) molecular associates of sodium 
stearate‒carbamazepine (CBZ) and sodium dodecyl sulfate‒CBZ with parallel (top) and 
perpendicular (bottom) orientation of the molecules. Calculations performed at B97-D3/6-31G(d,p) 
level (geometry) and B2PLYP-D3/def2-QZVPP level (energy). Carbon – grey, hydrogen – white, 
nitrogen – blue, oxygen – red, sulfur – yellow, sodium – purple. 
 
In solution the surfactant molecules are expected to exhibit some conformational freedom, thus we 
have also estimated the interaction strength of the CBZ molecules with bent conformations of the 
surfactants. While fully bent, the surfactants expose both their polar and non-polar parts towards 
interaction with the CBZ molecule, and the resulting binding strength is substantially higher for 
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sodium dodecyl sulfate (-28.4 kJ/mol) than for sodium stearate (-17.5 kJ/mol) (Fig. SI3 in the 
Supporting Information). 
Taking into account the above considerations and the fact that it is not SDS (12-carbon tail) but 
sodium stearate (17-carbon tail) that promotes nucleation of polymorph II, it appears that the 
sufficient length of the hydrocarbon chain may be one of the key structural parameters of a surfactant 
to efficiently template the nucleation of form II. Another factor may be the interaction strength and 
the number of solute molecules (CBZ) bound to the ionic part of a surfactant. It seems sensible to 
expect that more solute molecules strongly bound to the ionic ‘head’ of the SDS surfactant would 
create greater steric hindrance and would disturb other CBZ molecules from potentially templating 
on the hydrocarbon backbone more than it would be in the case of sodium stearate. Also, the 
significantly higher binding strength of the CBZ molecule to the bent conformation of SDS suggests 
that in solution the availability of this surfactant in its linear conformation (which appears to be the 
preferred conformation to template channels and columns of the Form II crystal) may be lower than 
in the case of sodium stearate.  
A possible mechanism of the surfactant-templated nucleation of CBZ form II is proposed in Figure 
10.  
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Figure 10 - A proposed mechanism for the surfactant-templated nucleation of the carbamazepine 
form II.   
 
Due to similar non-polar character of both the hydrocarbon tail of surfactant and the hydrocarbon 
rings of CBZ, at the pre-nucleation stage the solute molecules are expected to circle the surfactant’s 
backbone with their hydrophobic parts while pointing out the H-bond capable polar groups. Such a 
CBZ-circled surfactant column could gradually bind the available CBZ molecules or might attach 
through an array of H-bonds to a similar column. In both the cases, a Form II crystal-like columnar 
arrangement of the CBZ dimers could be created. A final refinement of the structure would involve 
removal of the templating surfactant molecules.  
The other additive, which is also a CBZ form II promoter, i.e. Eudragit L-100, most probably 
exhibits a different mechanism of polymer-templated nucleation. Eudragit L-100 is a linear 
copolymer of methacrylic acid and methyl methacrylate, thus its polymeric chain features carboxylic 
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groups (hydrophilic) and ester groups (predominantly hydrophobic) (see Fig. 7). Our DFT 
computations show that a CBZ molecule can bind by 9 kJ/mol stronger to carboxylic group of acetic 
acid (∆Ebind = -63.3 kJ/mol) than to another CBZ molecule (∆Ebind = -54.3 kJ/mol) (see Fig. 8). This 
suggests that CBZ molecules may preferentially bind to the carboxylic groups of the polymer, 
instead of forming CBZ-CBZ dimers. This could result in alignment of the CBZ molecules alongside 
the polymer’s linear chain, which seems to be a prerequisite for the formation of channels and 
columns of CBZ dimers as present in the crystal lattice of form II.  
Besides the proposed hypothesis of templating and stabilizing the metastable Form II at the 
nucleation stage (using sodium stearate or Eudragit L-100), the appearance of the Form II may 
alternatively result from the inhibiting effect of sodium stearate and Eudragit L-100 on the 
polymorphic transition of the already formed metastable Form II crystals. Thus the Oswald’s rule of 
stages, which postulates transformation to the more stable Form III, could not be followed in 
presence of these two additives. 
 
Conclusions 
It has been demonstrated that the polymorphic outcome of carbamazepine (CBZ) can be controlled 
when using a CO2-antisolvent crystallization method in combination with a certain additive type. In 
contrast, when using the same set of the additives, a solvent evaporation method provided mixtures 
of different polymorphs. Our SEM and PXRD results showed unanimously that sodium stearate and 
Eudragit L-100 as additives favor formation of needle-shaped crystals of CBZ form II, whereas 
KVA64, SDS, ethyl cellulose, and maltitol lead to formation of blocky-shaped crystals of CBZ form 
III. 
A molecular-level analysis revealed that the specific packing of the columns in the form II crystal 
results in formation of empty channels featuring hydrocarbon-terminated (hydrophobic) walls. We 
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propose that the specific arrangement of columns and channels of the form II crystal would emerge 
in the nucleation process due to conjunction of the non-polar parts of CBZ molecules with the non-
polar tail of a surfactant. Another additive leading to formation of pure polymorph II is Eudragit L-
100. Our DFT calculations show that carboxylic groups, which are present in the linear polymeric 
backbone of Eudragit L-100, exhibit stronger binding to CBZ molecules as compared to the CBZ-
CBZ dimer (being present in all the three polymorphs). This suggests that, through its carboxylic 
groups, Eudragit L-100 may form relatively stable complexes with the CBZ molecules, which if 
aligned, could facilitate columnar arrangement - a feature of the CBZ form II crystal.  
We believe that the proposed mechanistic insights can be related to similar systems, i.e. crystals 
possessing empty channels and/or columnar arrangement in their structures, and also to other 
additives, having structural features similar to the CBZ form II promoters, i.e. sodium stearate and 
Eudragit L-100. Another interesting point worth further exploration would be a systematic study of 
different surfactants, varied by length of the hydrocarbon tail and the type of a polar head, on their 
efficiency in nucleating/stabilizing the CBZ form II.      
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Supporting Information 
Experimental findings on the crystallization of carbamazepine by solvent evaporation, image 
analysis of carbamazepine samples produced by the gas antisolvent method and DFT equilibrium 
geometries of molecular associates of surfactants with carbamazepine are provided as Supporting 
Information. 
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Synopsis 
This work explores the mechanisms underlying the influence of selected additives in the 
crystallization of distinct polymorphic forms of carbamazepine using a gas antisolvent process. The 
type of additive used in the CO2-antisolvent crystallization process impacted both the product 
crystals polymorphic form and size. A detailed molecular-level analysis along with high-level DFT 
calculations provides a mechanistic insight into the surfactant-templated nucleation of 
carbamazepine polymorph II. 
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